Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CLARK WELLS GRIFFITH

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1588666242
CMS profile
117114
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$551.75

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $530.21 32
Gift $21.54 27

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ASCEND Therapeutics US, LLC $117.03 42
Gynesonics, Inc. $73.86 1
MILLICENT US INC $66.91 2
MAYNE PHARMA INC. $64.96 3
Organon LLC $51.82 2
PFIZER INC. $42.87 2
Minerva Surgical, Inc $22.80 1
Myovant Sciences Inc. $21.69 1
TherapeuticsMD, Inc. $21.24 1
Exeltis, USA Inc. $20.97 1
Meditrina $16.04 1
CooperSurgical, Inc. $15.84 1
ABBVIE INC. $15.72 1

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CLARK WELLS GRIFFITH

NPI 1588666242 · CMS profile ID 117114

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588666242?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CLARK WELLS GRIFFITH, NPI 1588666242, CMS profile ID 117114. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588666242?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CLARK WELLS GRIFFITH, NPI 1588666242, CMS profile ID 117114. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588666242?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CLARK WELLS GRIFFITH, NPI 1588666242, CMS profile ID 117114, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1588666242?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $551.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ASCEND Therapeutics US, LLC $8.7202/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896685165 CMS
ASCEND Therapeutics US, LLC $0.1202/16/2022 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896685167 CMS
ASCEND Therapeutics US, LLC $0.2002/16/2022 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896685169 CMS
ASCEND Therapeutics US, LLC $0.5002/16/2022 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896685171 CMS
ASCEND Therapeutics US, LLC $1.6002/16/2022 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896685173 CMS
MAYNE PHARMA INC. $24.8102/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959926897 CMS
ASCEND Therapeutics US, LLC $0.5002/08/2022 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896685089 CMS
ASCEND Therapeutics US, LLC $0.7701/24/2022 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896684957 CMS
ASCEND Therapeutics US, LLC $1.6001/24/2022 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896684959 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $566.40 30
PY2020 $123.67 7
PY2021 $161.88 7
PY2022 $551.75 59
PY2023 $744.98 44
PY2024 $616.01 23
PY2025 $319.74 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $81,596.13 82
PY2024 Principal investigator $370,140.69 178
PY2023 Principal investigator $359,658.81 189
PY2022 Principal investigator $123,461.10 79
PY2021 Principal investigator $81,749.81 69
PY2020 Principal investigator $98,787.36 50
PY2019 Principal investigator $178,787.90 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

82 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sumitomo Pharma America, Inc. $1,306.13 12/24/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176657873
Principal investigator 1 Sumitomo Pharma America, Inc. $600.75 12/18/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176657493
Principal investigator 1 Sumitomo Pharma America, Inc. $1,500.00 11/20/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176655855
Principal investigator 1 Sumitomo Pharma America, Inc. $500.00 11/20/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176655859
Principal investigator 1 Sumitomo Pharma America, Inc. $276.75 11/20/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176655863
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 11/20/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176655867
Principal investigator 1 Sumitomo Pharma America, Inc. $438.75 10/14/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176650877
Principal investigator 1 Sumitomo Pharma America, Inc. $22.41 09/11/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176647477
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 09/11/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176647481
Principal investigator 1 Sumitomo Pharma America, Inc. $1,306.13 08/27/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644346
Principal investigator 1 Sumitomo Pharma America, Inc. $1,306.13 08/27/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644351
Principal investigator 1 Sumitomo Pharma America, Inc. $1,306.13 08/27/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644354
Principal investigator 1 Sumitomo Pharma America, Inc. $1,407.38 08/27/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644358
Principal investigator 1 Sumitomo Pharma America, Inc. $34.00 08/27/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644362
Principal investigator 1 Sumitomo Pharma America, Inc. $600.00 08/27/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644366
Principal investigator 1 Sumitomo Pharma America, Inc. $500.00 08/27/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644369
Principal investigator 1 Sumitomo Pharma America, Inc. $22.73 08/27/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644373
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 08/27/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644377
Principal investigator 1 Sumitomo Pharma America, Inc. $1,000.00 08/21/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644124
Principal investigator 1 Sumitomo Pharma America, Inc. $438.75 08/21/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644127
Principal investigator 1 Sumitomo Pharma America, Inc. $1,000.00 08/21/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644132
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 08/21/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644136
Principal investigator 1 Sumitomo Pharma America, Inc. $634.50 08/21/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644139
Principal investigator 1 Sumitomo Pharma America, Inc. $190.00 08/21/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644143
Principal investigator 1 Sumitomo Pharma America, Inc. $190.00 08/21/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644147
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 08/21/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644151
Principal investigator 1 Sumitomo Pharma America, Inc. $540.00 08/21/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644154
Principal investigator 1 Sumitomo Pharma America, Inc. $540.00 08/21/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644158
Principal investigator 1 Sumitomo Pharma America, Inc. $220.00 08/21/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176644161
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 08/12/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176643853
Principal investigator 1 Sumitomo Pharma America, Inc. $190.00 08/12/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176643858
Principal investigator 1 Sumitomo Pharma America, Inc. $371.00 08/12/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176643861
Principal investigator 1 Sumitomo Pharma America, Inc. $3,918.39 08/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176643488
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 08/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176643492
Principal investigator 1 Sumitomo Pharma America, Inc. $796.50 08/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176643564
Principal investigator 1 Sumitomo Pharma America, Inc. $276.75 08/04/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176643258
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 08/04/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176643463
Principal investigator 1 Sumitomo Pharma America, Inc. $21.83 07/29/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176641512
Principal investigator 1 Sumitomo Pharma America, Inc. $220.00 07/29/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176641516
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 07/29/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176641519
Principal investigator 1 Sumitomo Pharma America, Inc. $220.00 07/25/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176641343
Principal investigator 1 Sumitomo Pharma America, Inc. $540.00 07/18/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176640734
Principal investigator 1 Sumitomo Pharma America, Inc. $26.21 05/28/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176635088
Principal investigator 1 Sumitomo Pharma America, Inc. $3,918.39 05/22/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176635027
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 05/15/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176634906
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 05/08/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176634533
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 04/24/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176633624
Principal investigator 1 Sumitomo Pharma America, Inc. $75.00 04/24/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176633628
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 04/17/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176633483
Principal investigator 1 Sumitomo Pharma America, Inc. $15,555.69 04/10/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176633212
Principal investigator 1 Sumitomo Pharma America, Inc. $16.52 04/04/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176632325
Principal investigator 1 Sumitomo Pharma America, Inc. $220.00 04/04/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176632329
Principal investigator 1 Sumitomo Pharma America, Inc. $220.00 04/04/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176632333
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 03/20/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176630655
Principal investigator 1 Sumitomo Pharma America, Inc. $100.00 02/20/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176628334
Principal investigator 1 Sumitomo Pharma America, Inc. $150.00 02/20/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176628336
Principal investigator 1 Sumitomo Pharma America, Inc. $7,020.90 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176626091
Principal investigator 1 Sumitomo Pharma America, Inc. $2,894.14 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176626095
Principal investigator 1 Sumitomo Pharma America, Inc. $100.00 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627178
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627182
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627186
Principal investigator 1 Sumitomo Pharma America, Inc. $150.00 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627232
Principal investigator 1 Sumitomo Pharma America, Inc. $1,100.25 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627237
Principal investigator 1 Sumitomo Pharma America, Inc. $220.00 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627242
Principal investigator 1 Sumitomo Pharma America, Inc. $220.00 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627247
Principal investigator 1 Sumitomo Pharma America, Inc. $325.00 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627251
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627255
Principal investigator 1 Sumitomo Pharma America, Inc. $940.00 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627260
Principal investigator 1 Sumitomo Pharma America, Inc. $940.00 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627264
Principal investigator 1 Sumitomo Pharma America, Inc. $48.37 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627307
Principal investigator 1 Sumitomo Pharma America, Inc. $11.91 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627314
Principal investigator 1 Sumitomo Pharma America, Inc. $35.66 02/06/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176627318
Principal investigator 1 Sumitomo Pharma America, Inc. $1,289.58 01/30/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176625083
Principal investigator 1 Sumitomo Pharma America, Inc. $1,073.25 01/23/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176624541
Principal investigator 1 Sumitomo Pharma America, Inc. $843.75 01/23/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176624545
Principal investigator 1 Sumitomo Pharma America, Inc. $843.75 01/23/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176624549
Principal investigator 1 Sumitomo Pharma America, Inc. $80.00 01/23/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176624554
Principal investigator 1 Sumitomo Pharma America, Inc. $101.25 01/23/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176624558
Principal investigator 1 Sumitomo Pharma America, Inc. $101.25 01/23/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176624562
Principal investigator 1 Sumitomo Pharma America, Inc. $1,012.50 01/23/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176624566
Principal investigator 1 Sumitomo Pharma America, Inc. $695.25 01/23/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176624569
Principal investigator 1 Sumitomo Pharma America, Inc. $587.25 01/23/2025 Non-covered Recipient Entity
DCT HCWC LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176624573